The Biology and Pathology of FSGS
At a Glance
FSGS is kidney scarring caused by injury to podocytes, the cells that help filter blood. A biopsy and clinical evaluation help determine whether it is primary, secondary, genetic, or undetermined and identify the Columbia scar variant.
Understanding the biology of Focal Segmental Glomerulosclerosis (FSGS) requires looking deep into the kidney’s filtering units. While your diagnosis describes a pattern of scarring, the “why” and “how” behind that scarring are found at the cellular level.
The Role of the Podocyte
The most important cell in the story of FSGS is the podocyte. These are specialized cells that wrap around the tiny blood vessels in your kidney’s filters (glomeruli) like fingers [1]. Their job is to form a final barrier that keeps essential proteins in your blood while letting waste products pass into your urine.
In FSGS, the primary problem is podocyte injury [2]. When these cells are stressed or damaged, they lose their complex shape—a process called foot-process effacement [3]. As podocytes become more damaged, they can detach from the filter and be lost in the urine. Because adult podocytes have a very limited capacity to repair or replace lost cells, the areas where they are missing become “naked,” leading to the formation of scar tissue (sclerosis) [4].
Why Biopsies Can Be Tricky
FSGS is notoriously difficult to diagnose because it is “focal,” meaning it only affects some filters while others look perfectly normal [1].
- The Sampling Problem: A kidney biopsy only takes a tiny sliver of tissue. If the needle misses the specific filters that have scars, the biopsy might look normal under a regular light microscope [5].
- The Overlap with MCD: This often leads to a “missed” diagnosis or a label of Minimal Change Disease (MCD). In MCD, the filters look normal under a light microscope, but protein is still leaking out. It is important to know that electron microscopy (which zooms in thousands of times) shows diffuse podocyte foot-process effacement in both FSGS and MCD. FSGS is established by finding the focal segmental sclerosis scar on light microscopy, while electron microscopy supports the assessment and helps exclude other diseases; it cannot by itself distinguish FSGS from MCD when a sclerotic lesion is not sampled [6].
The Four Categories of FSGS
Following the KDIGO 2021 guidelines, doctors now group FSGS based on its underlying biological cause rather than just how it looks [7].
1. Primary FSGS
This is a clinical-pathologic diagnosis, based on nephrotic syndrome, diffuse effacement, and no secondary or genetic causes. It is proposed to be caused by a “circulating factor” in the blood—an unidentified substance that directly injures the podocytes [8]. It typically causes sudden, severe swelling and high protein loss. On a biopsy, primary FSGS typically shows diffuse foot-process effacement, meaning the podocyte damage is widespread even if the scarring is only in a few spots [3].
2. Secondary FSGS
This occurs when the podocytes are injured as a “side effect” of another condition. This is often called maladaptive FSGS because it happens when the kidney is trying to adapt to being overworked [1].
- Common Causes: Obesity, high blood pressure, sleep apnea, or having only one functioning kidney [8].
- Other Triggers: Certain viruses (like HIV or CMV) and specific medications can also trigger secondary FSGS [1].
3. Genetic FSGS
This is caused by mutations in the genes that build or maintain the podocytes [9]. It is often suspected if the disease runs in the family or if it doesn’t respond to standard immune-suppressing treatments [8]. A specific genetic risk factor called APOL1 is especially common in people of West African descent; note that APOL1 risk variants are complex susceptibility factors rather than proof of a monogenic inherited disease [10].
4. FSGS of Undetermined Cause
In some cases, the biopsy shows FSGS, but the patient doesn’t have the severe symptoms of primary FSGS or an obvious secondary cause like obesity [11]. These cases are kept in this “undetermined” category so doctors don’t rush into treatments that might not work [7].
The 5 Columbia Histologic Variants
While the categories above describe the cause, the Columbia classification describes the appearance of the scars under the microscope. Your pathology report will likely mention one of these five variants [12]. These variants are probabilistic associations, not absolute predictions:
| Variant | What the Pathologist Sees | Why It Matters |
|---|---|---|
| Collapsing | The filter “collapses” and the podocytes grow out of control [13]. | Often a more aggressive form; frequently linked to viruses or specific genes [14]. |
| Tip | The scar is located exactly where the filter connects to the kidney’s drainage tube [12]. | Generally has a better outlook and may respond well to treatment [12]. |
| Perihilar | The scar is at the “doorway” where blood vessels enter the filter [12]. | Common in secondary FSGS caused by obesity or high blood pressure [12]. |
| Cellular | The scar contains an overgrowth of cells within the filtering loops [12]. | A rare variant [12]. |
| NOS | “Not Otherwise Specified”—a catch-all for scars that don’t fit the other four [12]. | The most common variant found on biopsies [12]. |
By combining the etiologic category (the cause) with the histologic variant (the appearance), your medical team can build a precise map of your disease and choose the best path forward [7].
Common questions in this guide
How does podocyte damage lead to FSGS?
Can a kidney biopsy miss FSGS?
What does diffuse foot-process effacement mean in FSGS?
What are the four main causes or categories of FSGS?
What does a Columbia variant on an FSGS pathology report mean?
When should someone with FSGS consider genetic testing?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Focal segmental glomerulosclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What percentage of my kidney's filters (glomeruli) were affected by scarring in the biopsy sample?
- 2.Does my biopsy report mention 'diffuse foot-process effacement,' and what does that suggest about the cause of my FSGS?
- 3.Which of the five Columbia variants (Tip, Collapsing, Cellular, Perihilar, or NOS) did the pathologist find?
- 4.Is there any evidence on my biopsy of 'glomerular hypertrophy' or other signs that my kidneys are being overworked?
- 5.Should we consider genetic testing to see if my FSGS is caused by a gene mutation, especially if I don't respond to steroids?
References
References (14)
- 1
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.
Shabaka A, Tato Ribera A, Fernández-Juárez G
Nephron 2020; (144(9)):413-427 doi:10.1159/000508099.
PMID: 32721952 - 2
Mechanisms of Scarring in Focal Segmental Glomerulosclerosis.
Zhong J, Whitman JB, Yang HC, Fogo AB
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2019; (67(9)):623-632 doi:10.1369/0022155419850170.
PMID: 31116068 - 3
What are we missing in the clinical trials of focal segmental glomerulosclerosis?
Zand L, Glassock RJ, De Vriese AS, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(suppl_1)):i14-i21 doi:10.1093/ndt/gfw324.
PMID: 28391338 - 4
Mechanisms of Scarring in Focal Segmental Glomerulosclerosis.
Sun K, Xie Q, Hao CM
Kidney diseases (Basel, Switzerland) 2021; (7(5)):350-358 doi:10.1159/000517108.
PMID: 34604342 - 5
Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V, López D, Boixadera E, et al.
BMC nephrology 2017; (18(1)):49 doi:10.1186/s12882-017-0452-6.
PMID: 28158993 - 6
Electron microscopic findings suggestive of focal and segmental glomerulosclerosis in patients with steroid-resistant nephrotic syndrome.
Nili F, Saboori F, Jahanzad I, Mehrazma M
Ultrastructural pathology 2019; (43(1)):6-12 doi:10.1080/01913123.2019.1584258.
PMID: 30835594 - 7
Indications for genetic testing in adults with focal segmental glomerulosclerosis.
Pilco-Terán M, Shabaka A, Furlano M, et al.
Nefrologia 2025; (45(2)):135-149 doi:10.1016/j.nefroe.2025.02.001.
PMID: 39952830 - 8
Focal Segmental Glomerulosclerosis.
Rosenberg AZ, Kopp JB
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(3)):502-517 doi:10.2215/CJN.05960616.
PMID: 28242845 - 9
Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults.
Lepori N, Zand L, Sethi S, et al.
Clinical kidney journal 2018; (11(2)):179-190 doi:10.1093/ckj/sfx143.
PMID: 29644057 - 10
A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations.
Bonilla M, Efe O, Selvaskandan H, et al.
Kidney medicine 2024; (6(6)):100826 doi:10.1016/j.xkme.2024.100826.
PMID: 38765809 - 11
Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection.
Miao J, Pinto E Vairo F, Hogan MC, et al.
Mayo Clinic proceedings 2021; (96(9)):2342-2353 doi:10.1016/j.mayocp.2021.01.037.
PMID: 34120753 - 12
Pathogenesis of Focal Segmental Glomerulosclerosis.
Lim BJ, Yang JW, Do WS, Fogo AB
Journal of pathology and translational medicine 2016; (50(6)):405-410 doi:10.4132/jptm.2016.09.21.
PMID: 27744657 - 13
The evolution of morphological variants of focal segmental glomerulosclerosis: a repeat biopsy-based observation.
Zhong Y, Xu F, Li X, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(1)):87-95 doi:10.1093/ndt/gfv245.
PMID: 26160893 - 14
Severe Acute Respiratory Syndrome Coronavirus 2 Induced Focal Segmental Glomerulosclerosis.
Malik IO, Ladiwala N, Chinta S, et al.
Cureus 2020; (12(10)):e10898 doi:10.7759/cureus.10898.
PMID: 33194467
This page is for informational purposes only and does not constitute medical advice. Your nephrologist and pathologist should interpret your biopsy, genetic tests, and treatment options in the context of your specific care.